Malignant Melanoma Clinical Trials

A listing of Malignant Melanoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 7 clinical trials
UPCC 09618: Neoadjuvant PD-1 Blockade in Patients with Stage IIB/C Melanoma

The main purpose of this study is to determine the rate of positive sentinel lymph nodes (i.e. the closest draining lymph node(s) to the primary melanoma site) and to test whether treatment with pembrolizumab before surgery to remove melanoma reduces the rate of positive sentinel lymph nodes in patients with …

  • 0 views
  • 19 Feb, 2024
  • 1 location
UPCC 03621: A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02B (Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

TBD

  • 0 views
  • 19 Feb, 2024
  • 1 location
UPCC 04621: A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02C (Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy

TBD

  • 0 views
  • 19 Feb, 2024
  • 1 location
PHASE I TRIAL OF AUTOLOGOUS T CELLS ENGINEERED TO EXPRESS NY-ESO-1 TCR AND GENE EDITED TO ELIMINATE ENDOGENOUS TCR AND PD-1

This is a Phase 1 first-in-human trial proposed to determine the safety profile and manufacturing feasibility of a single infusion of NYCE T cells on adult patients with myeloma, synovial sarcoma, and myxoid/round cell liposarcoma, and melanoma who have relapsed or refractory tumors expressing NY-ESO-1 antigen.

  • 0 views
  • 19 Feb, 2024
  • 1 location
Substudy: Understanding COVID-19 vaccine responses in the setting of immunotherapy

This study is designed to better understand antibody responses in the setting of PD-1 blockade compared to other anti-cancer therapies in melanoma patients. Identification of impaired vaccine responses would have major implications for vaccination in the setting of immunotherapy and will also elucidate the role of PD-1 signaling in generating …

  • 0 views
  • 19 Feb, 2024
  • 1 location
UPCC 01617: A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic Melanoma

Request for collaborative review: WIRB serving as IRB of record.

  • 0 views
  • 19 Feb, 2024
  • 1 location
UPCC 02619: Adjuvant Nivolumab Or Ipilimumab + Nivolumab Determined By Pathological Response To A Single Dose Of Neoadjvuant Nivolumab

Subjects with Stage III resectable melanoma will receive adjuvant therapy, nivolumab or ipilimumab plus nivolumab, based on whether a pathologic complete response (CR) or near CR (less than 10% viable tumor cells) is achieved with one dose of nivolumab in the neoadjuvant setting followed by surgery.

  • 0 views
  • 19 Feb, 2024
  • 1 location